NUP98 and acute myeloid leukemia: The subsequent AUGMENT-102 trial (NCT05326516) investigated revumenib in combination with fludarabine and cytarabine (FLA) in 27 patients with R/R AML harboring NPM1m, KMT2Ar, or NUP98 rearrangements [17].